Comparison of Efficacy of Bupivacaine in Supraclavicular Block With or Without Dexmedetomidine
CompletedPhase 4NCT05991375
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
End-stage renal disease (ESRD) patients are coming for Brachial vein transposition surgery. Patients were randomly allocated using sealed opaque envelope bearing A- (Injection bupivacaine (0.25%) 28 ml plus 2 ml. normal saline) and B-Injection bupivacaine (0.25%) 28 mL plus dexmedetomidine I ug/kg diluted to 2 ml). Supraclavicular block under ultrasound and nerve stimulator guidance was performed.
Study details
- Official title
- A Randomized Comparative Evaluation Of The Effects Of Dexmedetomidine As An Adjuvant With Bupivacaine In Supraclavicular Block In Chronic Renal Failure Patients Undergoing Basilic Vein Transposition Surgery
- Conditions
- Interventions
- Drug: DEXmedetomidine
- Other: saline
- Sponsor
- Sindh Institute of Urology and Transplantation
- Start date
- 2021-02-15
- Primary completion
- 2021-04-30
- Sex
- All
- Age range
- from 18 Years to 65 Years
- Results posted
- No results posted in this snapshot
- Countries
- Pakistan
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Chronic renal failure patients who will undergo elective basilic vein transposition surgery * Either gender * ASA III * Age 18-65 years. Exclusion Criteria: * Mentally challenged * Pregnancy. * Hypersensitivity to bupivacaine or dexmedetomidine * Seizures * Neck swelling (hematoma, lipoma, tumor, thyroid) * Neuromuscular dystrophy * Bleeding disorders
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT05991375